Once dermatomyositis is diagnosed, early treatment is now usually advocated. Dermatomyositis in children is similar to, but different from, dermatomyositis in adults. Treatment options are determined by the severity of the disease, the tissues and organs involved, and the response to treatment. Treatment of dermatomyositis consists of general treatment, treatment of skin damage, and treatment of muscle lesions. In a small number of patients, treatment of complications and other systemic diseases is also included. The main goal of treatment is to prevent complications and reduce mortality. General treatment: Patients with severe muscle lesions need bed rest and avoid strenuous exercise to aggravate muscle damage. In children, special attention should be paid to the movement of joints to prevent joint ankylosis and contracture. Patients with swallowing difficulties should pay attention to choking and coughing when eating, not to eat in bed, and to give nasal feeding if necessary. Pay attention to prevent infection during treatment. Treatment of muscle disease: The main treatment method at present is still the systematic administration of corticosteroids, and the usual dose of prednisone is 1-2 mg/kg/d. After control, pay attention to the gradual reduction of the dose to prevent relapse. In order to reduce the toxic side effects of hormones, immunosuppressants or cytotoxic agents such as azathioprine and methotrexate can also be used in combination at an early stage. Pay attention to the gradual reduction of dosage under the guidance of doctors. When the above treatments are not effective, high-dose gammaglobulin shock therapy for 2-4 days per month for 6 months may be considered and may be effective. In addition, biologic agents such as rituximab may be used, but are reported to be ineffective for skin damage. Treatment of skin damage: Treatment of skin damage is usually refractory. Of note: a proportion of patients who first have skin damage without muscle damage (so-called myopathic dermatomyositis) may also later develop typical muscle damage, while in other patients skin damage may appear after muscle symptoms have been controlled. Treatment begins with protection from light and avoidance of light, which is usually associated with photosensitivity in this group of patients. Hydroxychloroquine (6-7 mg/kg/d) and chloroquine may be used, with the caveat that treatment may cause drug rash and bone marrow suppression, so periodic blood work is required. Cytotoxic agents such as methotrexate (MTX) and immunosuppressive agents are also effective. Gammaglobulin may be effective for both skin and muscle lesions. Treatment of calcium deposits: Calcium deposits are very common in children with dermatomyositis. The calcium channel blocker diltiazem has been reported to be partially effective. In conclusion, the treatment of dermatomyositis in children is a complex systemic project that requires close cooperation between patients, parents, and physicians. Special attention should be paid to the importance of gradual dose reduction and maintenance until the disease is in complete remission after it has been controlled and stabilized.